LOOK, FEEL AND LIVE BETTER
Pycnogenol® potently lowers blood sugar by retardation of dietary carbohydrate absorption

When dietary carbohydrates are absorbed into blood less rapidly, over extended time periods, the post-prandial glucose peaks redound less markedly, with physiologic glucose level sustained less markedly, with appetite rebound occurring significantly later after the previous meal. As a result, unhealthy blood sugar spikes are avoided, which spares blood vessels from harm to the endothelium, such as loss of vascular flexibility and dilatation which in turn may cause hypertension and hyper-coagulability.

The largest consumption of dietary carbohydrates originates from starch-bearing foods. Starch is a macromolecule consisting of millions of connected glucose moieties. Digestion of starch involves enzymes, such as α-glucosidase and α-amylase, which disassemble starch to glucose in small intestine for subsequent transfer into the blood stream. The time required in small intestines for liberation of glucose from starchy foods is affected by other foods consumed with the meal. Especially vegetable flavonoids stall the release of glucose from starchy foods.
**Pycnogenol® more potently inhibits α-glucosidase than pharmaceutical glucosidase inhibitor acarbose**

Starchy dietary carbohydrates consumed require enzymatic cleavage to monomeric glucose, as only the latter may enter the blood stream. The cleavage is undertaken by particular enzymes in small intestines, predominantly α-glucosidase, which under ideal conditions occurs rapidly and typically may require only 15 minutes. Starch cleavage and glucose absorption take longer when the diet includes proteins and fats. Because flavonoids by nature display natural physical affinity to proteins, they attach also to enzymes, such as the α-glucosidase, which defers cleavage of starch to glucose. Pycnogenol® has a particularly high binding affinity to glucosidase with consequential potent retardation of carbohydrate absorption [Schäfer & Högger, 2007]. As an immediate result, blood sugar does not rise as rapidly and as high, instead sugar is absorbed for protracted time period after meals, thereby preventing unhealthy glucose spikes.

Analytical comparison for α-glucosidase inhibition suggests that Pycnogenol® is 200-fold more potent as compared to acarbose, and much more efficient than green tea extract or catechin.
The high potency of Pycnogenol® for α-glucosidase inhibition, and in consequence blood glucose lowering, is demonstrated to result from presence of particularly large procyanidin species present in the product.

Whereas essentially all flavonoid species exhibit some inhibitory activity to α-glucosidase, the particularly large procyanidins limited to Pycnogenol®, exhibit glucosidase-inhibitory potency by an order of magnitude greater.

**Pycnogenol® in blood sugar management**

Pycnogenol® assists individuals with borderline elevated blood sugar, as well pre-diabetes and type II diabetics, not requiring medication, to achieve significantly healthier blood sugar levels. In a study with 30 type II diabetic individuals, not requiring medication, Pycnogenol® was demonstrated to dose-dependently and significantly lower fasting and post-prandial glucose levels [Liu & Zhou et al., 2004].

Study participants were treated in succession with 50, 100 and 200 mg Pycnogenol® daily, for a period of three weeks for each dosage. A noticeable reduction with 50 mg daily Pycnogenol® supplementation is apparent after three weeks. Dose escalation showed significantly greater fasting- and post-prandial glucose reduction for 100 mg Pycnogenol® and 200 mg Pycnogenol®, respectively. Average HbA1c levels decreased continuously during the investigation from baseline 8.0 to 7.4. This study published in Diabetes Care, found that Pycnogenol® does not affect insulin levels. Pycnogenol® appears to facilitate blood sugar uptake by previously insulin-unresponsive body cells. Pycnogenol® therefore may offer a nutritional approach for people to prevent developing diabetes.

**Pycnogenol® improves Metabolic Syndrome**

Research suggests that Pycnogenol® helps arrest progression of metabolic syndrome to manifest type II diabetes [Belcaro et al., 2013]. One hundred and thirty seven participants with metabolic syndrome, presenting with all five risk factors (central obesity, high blood triglycerides, high LDL, low HDL and hypertension) were counselled for healthier life style including dietary advice, an educational programme and a moderate exercise programme. Seventy one subjects were additionally supplemented with Pycnogenol®. All subjects were surveyed for six months. This study identified significant fasting glucose improvements after three and six months of daily supplementation with Pycnogenol®.
Furthermore, study participants presented with significantly healthier systolic- and diastolic blood pressure, as well as significant cholesterol- and triglyceride reduction, which were statistically significant after six months study completion.

**Pycnogenol® taken in addition to medications, significantly further reduces blood glucose and cardiovascular risk factors in two independent studies**

Forty-eight individuals medicating with metformin and/or sulfonylurea, as well as thiazolidinediones, received in addition either Pycnogenol® or placebo [Zibadi et al., 2008]. Fasting glucose was significantly lower in subjects who received Pycnogenol® in addition to their standard medications, as compared to the control group which received placebo in addition to prescription medications.

Because prescription medications for diabetes exert pharmacologic activities which are distinct from Pycnogenol®s natural effects related to slowed starch digestion, the additional supplementation with Pycnogenol® yields significantly better blood sugar control. Study participants treated supplementing with Pycnogenol® presented with significantly lowered fasting glucose as well as with lowered HbA₁c.

The mean HbA₁c levels of participants in the study of Zibadi (2008) decreased from one month to the next in subjects supplementing with Pycnogenol®, with no identifiable improvements in the placebo group.

Further to significant lowering of blood sugar with Pycnogenol®, this study identified improvement of typical diabetic complications related to vascular-constriction, kidney function and LDL cholesterol. Pycnogenol® significantly lowered LDL cholesterol from mean 106.4 mg/dL to 93.7 mg/dL after twelve weeks, whereas no changes were identifiable for the placebo-treated group.

**Research demonstrates that Pycnogenol® taken as an adjunct to diabetes medications significantly further improves blood glucose management**

Another study corroborates the virtues of Pycnogenol®, when taken in addition to diabetes medication, for further improvement of hyperglycaemia [Liu & Wei al., 2004]. Seventy seven type II diabetic study participants continued their standard medication with metformin and/or sulfonylurea and received either 100 mg Pycnogenol® or placebo in addition. Despite applying conventional diabetes treatment, fasting glucose was
high at trial start with average 216 mg/dL. Blood sugar controlled in two weeks intervals showed glucose reduction in both groups, including placebo, which suggests better conventional treatment compliance. Yet, additional supplementation with Pycnogenol® statistical significantly further lowered fasting glucose than did prescription medication alone, thus underlining the proposition of Pycnogenol® as adjuvant treatment for optimal glycaemic control and prevention of diabetic complications.

Persisting and acute hyperglycaemia affects vascular function, which is critically involved in modulating vascular tone. Especially endothelial function is at risk, which regulates vascular tone, tissue blood perfusion and blood fluidity. Generation of vasodilatory nitric oxide (NO) is impaired in hyperglycaemia and insulin resistance, resulting in increased vascular constriction, blood pressure elevation and a pro-thrombotic state. The endothelial dysfunction in diabetes leads to increased vascular constriction with inability for vascular relaxation, representing the major culprit in the pathogenesis of diabetic complications. These complications have different consequences for large blood vessels in cardiovascular health issues and small capillary, micro-circulation related diabetic complications, resulting from impaired tissue perfusion.

**Pycnogenol® improves Macrovascular Complications in Diabetes**

Major cardiovascular risk factors are related to type II diabetes and metabolic syndrome: hypertension dyslipidaemia, oxidative stress, insulin resistance and a pro-thrombotic state. Pycnogenol® is demonstrated to contribute to all these cardiovascular health parameters. Pycnogenol® is described to dose-dependently decrease platelet aggregation in humans and correspondingly contributes to prevention of thromboses [Pütter et al., 1999; Belcaro et al. 2004]. In a clinical setting Pycnogenol® was demonstrated to significantly improve flow-mediated vasodilatation in coronary artery patients, in double-blind, placebo-controlled, cross-over study design [Enseleit et al., 2012].

**Pycnogenol® alleviates Micro-circulatory Complications in Diabetes**

Impaired blood micro-circulation in diabetes represents the cause for a range of diabetic complications. Because Pycnogenol® contributes to restoration of endothelial function, with greater availability of vessel-expanding nitric oxide, tissue perfusion with oxygen-
rich blood is improved. Correspondingly, Pycnogenol® is demonstrated in clinical trials to significantly alleviate diabetic complications.

**Diabetic Ulcers**
Diabetic individuals commonly experience that even tiny bruises and wounds heal extremely slowly or even hardly at all. This is a result of capillaries being unable to perfuse harmed tissues with required oxygen- and nutrient-rich blood, because perfusion with arterial blood is insufficient. Pycnogenol® improves capillary relaxation and hence vessel diameter, increasing oxygen and nutrient supply and, in turn wounds heal well [Belcaro et al., 2006; Cesarone et al., 2006].

**Diabetic Nephropathy**
Three clinical studies have ascribed improved kidney function for Pycnogenol®, as judged from significantly lowered urinary albumins in diabetic and hypertensive individuals. [Zibadi et al., 2008; Stuard et al., 2010;].

Pycnogenol® was demonstrated in three clinical studies, one of which represents a multi-centre field study with 1169 diabetic patients, to be helpful for treatment and prevention of diabetic retinopathy [Spadea et al., 2001; Schönlau et al., 2002; Steigerwalt et al., 2009]. For more information please refer to Pycnogenol® FOR EYE HEALTH brochure.

**Diabetic Retinopathy**
In diabetes the smallest capillaries bear the greatest burden, as they are the most fragile vessels, and once damaged, are difficult to heal because of the diminished blood flow and lack of nutrients. This is the case with retinal light sensing cones and rods, which are insufficiently nourished in diabetic retinopathy, progressively affecting vision. At advanced stages leaking dysfunctional retinal capillaries spill blood into retina causing irreversible vision loss. Left untreated, retinopathy may progress to more severe forms characterised by compensatory growth of new capillaries, causing scarring and eventually blindness.
REFERENCES

1. Gulati OP.
2. Schäfer A, Högger P.
3. Liu X, Zhou HJ, Rohdewald P.
5. Zibadi S, Rohdewald PJ, Park D, Watson RR.
10. Cesarone MR et al.
12. Spadea L and Balestrazzi E.
13. Schönlaub F, Rohdewald P.
The information provided in this document is for professional use only. Statements and information provided herein have not been evaluated by the Food and Drug Administration or other health authorities. This product is not intended to diagnose, treat, cure or prevent any disease. Horphag Research supplies Pycnogenol® as a raw material to manufacturers of finished products. Therefore, Horphag Research makes no claims regarding the use of finished products and each manufacturer is responsible for ensuring that any claims it chooses to make in connection with the use of its finished products fully comply with the regulatory and legal requirements of the locations in which it markets its products.

Pycnogenol® is a registered trademark of Horphag Research.

Use of this product is protected by one or more U.S. patents and other international patents.